Actively Recruiting
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Led by baotai Liang · Updated on 2025-11-18
93
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
Sponsors
B
baotai Liang
Lead Sponsor
T
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk/very high-risk, regional lymph node-metastatic, or metastatic prostate cancer before radical prostatectomy through clinical trials, thereby identifying an effective treatment for patients with advanced prostate cancer.
CONDITIONS
Official Title
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years to 85 years
- Histologically or cytologically confirmed prostate cancer
- Localized high-risk/very high-risk prostate cancer defined by clinical stage T3-T4, Gleason score 8, primary Gleason pattern 5, or PSA > 20 ng/mL, without local lymph node or distant metastasis
- Prostate cancer with local lymph node metastasis but no distant metastasis
- Metastatic prostate cancer confirmed by imaging
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1
- Able to voluntarily sign informed consent and adhere to treatment and follow-up
You will not qualify if you...
- Any previous or ongoing prostate cancer treatment including radiotherapy, chemotherapy, or androgen deprivation therapy
- History of previous prostatectomy
- Severe underlying medical, psychiatric, or psychological diseases affecting treatment as judged by investigator
- Known allergy to study drugs
- Refusal to undergo radical prostatectomy
- Deemed ineligible for the clinical trial by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongda Hospital
Nanjing, Jiangsu, China, 210009
Actively Recruiting
Research Team
R
resident doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here